GRAIL
GRAIL Laboratory Overview
GRAIL is a healthcare and biotechnology company focused on multi-cancer early detection (MCED) through advanced blood testing. Its mission is to detect cancer earlier—often before symptoms appear—when treatment is more effective and survival rates are significantly higher. Early-stage cancer detection is one of the most important factors influencing long-term outcomes, making blood-based cancer screening an emerging area in preventive and precision medicine.
Using next-generation genomic sequencing, large population-scale clinical trials, and advanced machine-learning algorithms, GRAIL analyzes fragments of tumor-derived DNA circulating in the bloodstream (cell-free DNA). These fragments can act as molecular signals of cancer. By identifying these signals and predicting the likely tissue or organ of origin, GRAIL aims to help clinicians detect and localize cancer earlier than traditional methods alone.
GRAIL develops and offers blood tests for early cancer detection, including multi-cancer screening tests designed to identify dozens of cancer types from a single blood draw. These tests are intended to complement—not replace—standard screening methods such as mammograms, colonoscopies, cervical screening, and low-dose CT scans. The goal is to expand screening access to cancers that currently lack recommended routine screening.
The company’s technology platform is supported by large clinical validation studies involving tens of thousands of participants. By combining genomic data, clinical outcomes, and artificial intelligence, GRAIL continues to advance research into cancer biology, early detection, and population-level screening strategies.
Laboratory standards and accreditation
Testing associated with GRAIL is performed in laboratories that meet recognized clinical laboratory quality standards, including:
-
Clinical Laboratory Improvement Amendments (CLIA) certification
-
College of American Pathologists (CAP) accreditation
-
Additional international quality and laboratory standards where applicable
These certifications help ensure analytical accuracy, reliability, and consistent testing quality.
Why early cancer detection matters
Many cancers are more treatable—and sometimes curable—when found at an early stage. Blood-based multi-cancer screening represents a growing field in oncology that aims to detect cancer signals earlier, guide diagnostic evaluation, and support more timely treatment decisions.
GRAIL’s ongoing research and clinical development efforts are focused on improving the accuracy, accessibility, and clinical utility of early cancer detection testing across diverse populations.
Show more
Popular test panels by GRAIL:
Galleri by GRAIL is a multi-cancer early detection (MCED) blood test designed to screen for dozens of serious cancers, including many that currently have no standard screening options. By analyzing fragments of DNA released into the bloodstream by tu
Learn more